|
PRPS1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | <1E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
2.12159999999351E-05 |
| Normal-vs-Stage3 |
1.62458935193399E-12 |
| Normal-vs-Stage4 |
<1E-12 |
| Stage1-vs-Stage2 |
5.335900E-03 |
| Stage1-vs-Stage3 |
4.583600E-01 |
| Stage1-vs-Stage4 |
2.37859999999701E-05 |
| Stage2-vs-Stage3 |
3.136900E-03 |
| Stage2-vs-Stage4 |
4.27400000000411E-05 |
| Stage3-vs-Stage4 |
1.128100E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62436730732907E-12 |
| Normal-vs-AfricanAmerican |
1.62458935193399E-12 |
| Normal-vs-Asian |
1.62458935193399E-12 |
| Caucasian-vs-AfricanAmerican |
8.805200E-01 |
| Caucasian-vs-Asian |
7.888000E-02 |
| AfricanAmerican-vs-Asian |
2.575600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.62447832963153E-12 |
| Normal-vs-Female |
1.62436730732907E-12 |
| Male-vs-Female |
3.936000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
<1E-12 |
| Normal-vs-Age(81-100Yrs) |
2.335600E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.456200E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.155620E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.344600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.239400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.086000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.349000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.70229999999039E-06 |
| Classical-VS-Follicular |
4.02740000016166E-07 |
| Classical-VS-Other |
3.482800E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
4.25925961167195E-12 |
| Tall-VS-Other |
7.097800E-01 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
2.964200E-02 |
| Follicular-VS-Normal |
2.53449483622603E-11 |
| Other-VS-Normal |
3.48849837905618E-11 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.62447832963153E-12 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
4.23089999701531E-08 |
|
|
